Results of a Phase 2 Multicenter Study of Obinutuzumab plus Bendamustine in Patients with Previously Untreated CLL

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia

Bendamustine plus rituximab is a commonly used first-line treatment for chronic lymphocytic leukemia (CLL), with an overall response rate (ORR) of 96% and complete response (CR) of 31%. But there is substantial opportunity to improve patient outcomes. For instance, obinutuzumab in combination with chlorambucil significantly improved progression-free survival (PFS) and CR rate compared with rituximab and chlorambucil (Goede. 2014). Obinutuzumab is a glycoengineered, type II anti-CD20 monoclonal antibody. As such, this phase 2 study evaluates the efficacy and safety of bendamustine plus obinutuzumab as first-line treatment for patients with CLL.

A total of 102 patients with previously untreated CLL were enrolled. Patients received six 28-day cycles of bendamustine plus obinutuzumab by intravenous infusion. The median patient age was 61 years (range, 35-90 years); 68.6% were male; and 44.1% had Rai stage 3 to 4. The primary end point was CR assessed using International Workshop on CLL criteria. Secondary end points included ORR, PFS, overall survival, and minimal residual disease (MRD). The median follow-up at the time of analysis was 11.0 months.

The CR rate was 49.0% and ORR was 89.2% after 6 cycles. MRD negativity in blood, as measured by 4-color flow cytometry, was achieved in 42.7% of patients at the end of induction-response assessment and in 75.5% of patients at any time after induction. The most frequent adverse events of all grades were infusion-related reactions (72.5%), nausea (52.0%), and pyrexia (36.3%). The most frequent grade 3/4 adverse event was neutropenia (26.5%). The incidence of tumor lysis syndrome (all grade 3) was 4.9%. Three patients died; none of the deaths were related to study treatment or CLL.

Bendamustine plus obinutuzumab is an effective regimen for first-line treatment of patients with CLL, inducing a high CR rate after 6 cycles of therapy. No unexpected safety signals were observed.

Sharman JP, et al. ASCO Abstract 7523.

Related Items
iFCG for Previously Untreated Patients with CLL with Mutated IGHV and Non-Del(17p)
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Phase 1 Dose Escalation of Ibrutinib and Buparlisib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Mantle-Cell Lymphoma, and Follicular Lymphoma
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with CLL Intolerant to Prior Bruton’s Tyrosine Kinase or PI3Kδ Inhibitor Therapy
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
A Phase 1a/1b Study of a Novel BTK Inhibitor and Combination Products with Everolimus and Pomalidomide in Patients with CLL or Other B-Cell Lymphomas
Conference Correspondent published on June 8, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Patients with TN FL (PERSPECTIVE)
Conference Correspondent published on June 8, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Last modified: June 9, 2017
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME